CHICAGO, June 3, 2018/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced findings today from a Phase 2 study that showed treatment
More From BioPortfolio on "Erdafitinib Phase 2 Study Results Show Promise in the Treatment of Metastatic Urothelial Cancer"